SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

☑ Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

☐ Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*
Simcere Zaiming, Inc.

(Last) (First) (Middle)
20 ACORN PARK DR.

(Street)
CAMBRIDGE MA 02140

(City) (State) (Zip)

2. Issuer Name **and** Ticker or Trading Symbol
NextCure, Inc. [NXTC]
Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/10/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer (Check all applicable)
Director
10% Owner
Officer (give title below)
☑ Other (specify below)
Former 10% Owner

6. Individual or Joint/Group Filing (Check Applicable Line)
Form filed by One Reporting Person
☑ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	08/10/2026		S		30,000	D	$6.16	308,636	I	See Footnotes(1)(2)(3)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				

1. Name and Address of Reporting Person*
Simcere Zaiming, Inc.

(Last) (First) (Middle)
20 ACORN PARK DR.

(Street)
CAMBRIDGE MA 02140

(City) (State) (Zip)

1. Name and Address of Reporting Person*
Jiangsu Simcere Zaiming Pharmaceutical Co., Ltd.

(Last) (First) (Middle)
BUILDING 23, NO. 699-18
XUANWU AVENUE

(Street)
NANJING CITY, JIANGSU PROVINCE 210000

(City) (State) (Zip)

CHINA

(Country)

1. Name and Address of Reporting Person*

Simcere Zaiming Pharmaceutical Co., Ltd.

(Last)	(First)	(Middle)

NO. 20, YAOGUYIHENG ROAD
XIUYING DISTRICT

(Street)

HAIKOU CITY, HAINAN PROVINCE		570100
(City)	(State)	(Zip)

CHINA

(Country)

1. Name and Address of Reporting Person*

Simcere Pharmaceutical Group Ltd

(Last)	(First)	(Middle)

BUILDING 23, NO. 699-18
XUANWU AVENUE

(Street)

NANJING CITY, JIANGSU PROVINCE		210000
(City)	(State)	(Zip)

CHINA

(Country)

1. Name and Address of Reporting Person*

Ren Jinsheng

(Last)	(First)	(Middle)

BUILDING 23, NO. 699-18
XUANWU AVENUE

(Street)

NANJING CITY, JIANGSU PROVINCE		210000
(City)	(State)	(Zip)

CHINA

(Country)

1. Name and Address of Reporting Person*

Tang Renhong

(Last)	(First)	(Middle)

BUILDING 23, NO. 699-18
XUANWU AVENUE

(Street)

NANJING CITY, JIANGSU PROVINCE		210000
(City)	(State)	(Zip)

CHINA

(Country)

Explanation of Responses:

1. The securities reported herein were directly held by Simcere Zaiming, Inc. ("Simcere Zaiming") and may be deemed to have been indirectly beneficially owned by the other Reporting Persons.

2. Jiangsu Simcere Zaiming Pharmaceutical Co., Ltd. ("Jiangsu Zaiming") is the sole shareholder of Simcere Zaiming. Simcere Zaiming Pharmaceutical Co., Ltd. (formerly known as Hainan Simcere Zaiming Pharmaceutical Co., Ltd.) is the sole shareholder of Jiangsu Zaiming. Simcere Pharmaceutical Group Limited ("Simcere Group") is the controlling shareholder of Simcere Zaiming Pharmaceutical Co., Ltd. through several intermediate companies. Mr. Jinsheng Ren is the chairman of the board of directors of Simcere Group and a director of Simcere Zaiming Pharmaceutical Co., Ltd. Mr. Renhong Tang is a director of Simcere Group, the chief executive officer and chairman of the board of directors of Simcere Zaiming Pharmaceutical Co., Ltd., a director of Jiangsu Zaiming and the chief executive officer and sole director of Simcere Zaiming. Messrs. Ren and Tang may be deemed to be the beneficial owners having shared voting power and shared investment power over the securities described herein.

3. Each Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein. The filing of this statement shall not be deemed to be an admission that any Reporting Person is the beneficial owner of any of the reported securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or for any other purpose.

Remarks:

This Form 4 constitutes an exit filing for the Reporting Persons, as they have ceased to be beneficial owners of more than 10% of the Issuer's common stock and therefore are no longer subject to Section 16 of the Exchange Act as a result of the sale described above.

Simcere Zaiming, Inc., By: /s/ Renhong Tang, Chief Executive Officer	08/12/2026
Jiangsu Simcere Zaiming Pharmaceutical Co., Ltd., By: /s/ Renhong Tang, Director and Attorney-in-Fact	08/12/2026
Simcere Zaiming Pharmaceutical Co., Ltd., By: /s/ Renhong Tang, Chief Executive Officer and Chairman of the Board of Directors	08/12/2026
Simcere Pharmaceutical Group Limited, By: /s/ Jinsheng Ren, Chairman and Executive Director	08/12/2026
Ren Jinsheng, /s/ Jinsheng Ren	08/12/2026
Tang Renhong, /s/ Renhong Tang	08/12/2026
** Signature of Reporting Person	Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, *see* Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.